Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis

BACKGROUND: Faced with limited and inadequate treatment options for patients with advanced gastric cancer or gastroesophageal junction cancer (GC/GEJC), researchers have turned toward, with the support of promising clinical trials, anti-PD-1/anti-PD-L1 antibody therapy. But there are also different...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Li, Dong, Xian-Zhe, Xing, Xiao-Xuan, Cui, Xiao-Hui, Li, Lin, Zhang, Lan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667450/
https://www.ncbi.nlm.nih.gov/pubmed/33250966
http://dx.doi.org/10.4251/wjgo.v12.i11.1346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667450/
https://www.ncbi.nlm.nih.gov/pubmed/33250966
http://dx.doi.org/10.4251/wjgo.v12.i11.1346

Ejemplares similares